FDA ap­proves J&J's BC­MA-tar­get­ed bis­pe­cif­ic for mul­ti­ple myelo­ma

The FDA on Tues­day grant­ed ac­cel­er­at­ed ap­proval to John­son & John­son’s Tec­vayli (teclis­tam­ab), a BC­MA-di­rect­ed bis­pe­cif­ic an­ti­body, look­ing to head in­to an al­ready crowd­ed field …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER